Breaking news and real-time updates from the ASX small-cap market
Cleo Diagnostics taps Bio-Techne's US lab for pivotal validation of its pre-surgical ovarian cancer test ahead of a 510(k) FDA filing in H1 2027.
Challenger Gold maps a 2029 first production at Hualilán with US$267m capex, US$1.1b NPV, 35% IRR; 35,000m drilling to grow resources.
Optiscan Imaging advances ACL study, >80 cases imaged with InForm slide-free digital pathology, accelerating clinical validation and rollout.
Lode Resources reports high-grade tin-copper-silver lode at Montezuma; Moores Lode assays: 0.5m @ 7.3% Sn, 6.8% Cu, 863 g/t Ag.
St Barbara to sell New Simberi to Lingbao for $453m; unlocks value via royalties, plus potential dividend; focus shifts to Touquoy, Nova Scotia.
Manuka Resources reports high-grade gold at Pipeline Ridge: 32m @7.98 g/t, 8m @12.96 g/t; maiden resource due 2026, potential Wonawinta feed.
Cobre signs Chile ore deals to add ~300t Cu/month at Sierra Atacama from Q4 2026, boosting plant utilisation and cash flow ahead of 2027 open-pit expansion.
Red Sky Energy to re-enter Yarrow North 1, boosting Innamincka program; 0.24-0.89 Bcf gross gas target, ROG 20% share ~0.10 Bcf, capex ~A$3m, first gas 2027.
Biome Australia unveils larger two-month probiotic formats, boosting stock-keeping units and onshore manufacturing to drive demand in 2027.
PolarX hits 9.8% Cu over 24.8m at Caribou Dome, Alaska; mineralisation extends ~170m deeper, raising potential MRE uplift.
Echo IQ studies next steps after FDA finds EchoSolv HF 510(k) not substantially equivalent; will engage FDA directly while EchoSolv AS stays cleared.
Bannerman Energy launches $124m underwritten placement for Etango uranium project, advancing CNNC Overseas JV; CNOL deal due in Sept, construction in Q4 2026.
